[What is new in oncodermatology?].
News in the oncodermatology field this year were dominated by publications treating of melanoma and concerning in particular our increased knowledge of the various biological pathways involved in the distinct subtypes of melanoma. This molecular diversity is probably one of the reasons explaining the poor results of most of the clinical trials recently published because we don't know yet how to identify and select the right population of patients who could beneficiate from such or such therapy. However, some very encouraging results obtained with new protocols for adoptive immunotherapy have been published and we also hope that further results will confirm that the subset of KIT-mutated melanomas will beneficiate from an efficient targeted anti-Kit therapy. Besides melanoma, the scoop of the year was the discovery of a defective oncogenic polyomavirus which is very likely to be responsible for Merkel cell carcinoma.
Robert
C
C
Service de Dermatologie, Institut Gustave Roussy, Villejuif, France. caroline.robert@igr.fr
D000970:Antineoplastic Agents / Q000627:therapeutic use; D015266:Carcinoma, Merkel Cell / Q000188:drug therapy / Q000821:virology; D002986:Clinical Trials as Topic; D003880:Dermatology / Q000639:trends*; D019317:Evidence-Based Medicine; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D008495:Medical Oncology / Q000639:trends*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D018579:Patient Selection; D011120:Polyomavirus / Q000302:isolation & purification; D011379:Prognosis; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins